The first problem was a daughter’s lungs. In 1996, Martine Rothblatt founded United Therapeutics because her child had pulmonary arterial hypertension, a rare disease that makes the heart work against excessive pressure in the lung’s blood vessels. Rothblatt had already helped create satellite radio. This time, the signal she wanted to improve was biological: blood needed a less punishing route through the body.
- The business: prescription medicines for pulmonary hypertension and high-risk neuroblastoma.
- The wager: drug earnings help finance research into manufactured organs.
- The catch: a printed scaffold or a trial transplant still has to become a safe, reproducible treatment.
Thirty years later, the company has two connected pursuits. One sells treatments people can receive now. The other asks whether the shortage of transplantable organs can be tackled by manufacturing them. The distance between those pursuits is where this company gets interesting.
01 The molecule that learned new routes
Start with treprostinil, a prostacyclin analogue that helps dilate blood vessels. United Therapeutics turned it into several products. Remodulin delivers it by continuous infusion. Tyvaso delivers it through inhalation. Orenitram packages it as an extended-release tablet. Tyvaso DPI, approved in 2022, adds a dry-powder inhaler developed with MannKind.
For a patient, delivery is part of the treatment experience. A molecule must reach the body repeatedly, under ordinary daily conditions. Pumps, cartridges, training and refill logistics belong in that equation. United Therapeutics built expertise across the drug and its delivery, then worked with partners where it needed additional engineering.
The portfolio also includes Adcirca for PAH and Unituxin, an antibody used in combination treatment for pediatric high-risk neuroblastoma. This is a specialist business: physicians prescribe, specialty pharmacies distribute, and reimbursement affects access. United Therapeutics Cares helps eligible patients navigate coverage, affordability and treatment support. The useful invention sometimes includes getting the prescription through the paperwork.
02 The money that buys time
The scale is substantial. United Therapeutics reported $3.1827 billion in 2025 revenue, with Tyvaso products contributing $1.8782 billion. It recorded $550 million in research and development expense across the company. That figure is an annual expense, not a price tag for a finished organ.
Annual company revenue
Those earnings give long experiments room to continue. They also create dependence on existing products. Second-quarter 2026 revenue fell 2% from a year earlier to $783.3 million. Competition is tangible: Liquidia’s Yutrepia offers another inhaled treprostinil option for PAH. An October 2026 settlement addressed continued access and restrictions on new PH-ILD prescribing. The future still has to be paid for in a competitive present.
03 The factory at the end of the waiting list
A medicine can improve a patient’s condition without replacing a failing organ. United Therapeutics therefore works on several approaches to increasing organ supply. Its Lung Bioengineering subsidiary provides ex vivo lung perfusion services, helping transplant teams evaluate donor lungs outside the body. Elsewhere, the company is pursuing gene-edited pig organs and engineered tissues.
UKidney, an investigational kidney from a pig with ten gene edits, entered the EXPAND clinical-trial chapter with a first transplant announced in November 2025. Six human genes are added; four pig genes are inactivated. The aim is better compatibility and less rejection. That aim has to survive clinical scrutiny, including long-term monitoring.
The industrial preparations are already visible. On October 20, 2026, United Therapeutics announced its third designated pathogen-free xenograft production facility, in Houston. Biosecure environments control air, water, feed and entry procedures. Production capacity is being prepared while clinical development continues. A facility opening does not settle whether the products will earn approval.
The printed-lung effort follows another route. With 3D Systems, the company develops intricate scaffolds intended to be populated with cells. In March 2026, 3D Systems described 24 printers running at the Manchester research laboratory. It also explicitly described transplantable lungs as an R&D project with many steps remaining. The printers are working; the clinical destination remains ahead.
04 The study that said stop
Biology has already interrupted the expansion story. The PERFECT study tested inhaled treprostinil in pulmonary hypertension associated with COPD. In September 2022, the sponsor stopped it on the monitoring committee’s recommendation. Published results reported increased serious adverse events and suggestive evidence of increased mortality. The findings did not support that treatment approach in the studied population.
Success in a neighboring disease did not carry over. In October 2026, FDA cleared SUMMIT, a phase 2 trial of a different, soft-mist treprostinil delivery approach in PH-COPD. The company’s rationale includes tolerability in patients susceptible to cough and bronchospasm. That is a new hypothesis requiring evidence; clearance to study it establishes no clinical benefit.
Evidence has opened doors, too. A post-hoc lung-function finding in the INCREASE study helped prompt the TETON program in idiopathic pulmonary fibrosis. Positive phase 3 results supported an application the FDA accepted in September 2026. Review was expected to finish in late April 2027. Treating IPF remained investigational at this profile’s publication.
05 What travels beyond biotechnology
United Therapeutics became a public benefit corporation in 2021. Employees call themselves Unitherians. Its stated commitments include autonomy, career development and sustainable operations. Rothblatt’s leadership page offers a concise rule:
“A leader works for those they lead.”Martine Rothblatt
The transferable lesson is practical: solve an immediate problem well enough to fund the next one, improve delivery, and recruit expertise you lack. Copying that requires cash, capable partners and permission to keep testing. It becomes fragile when reimbursement weakens, a key product loses ground, or the next experiment fails. United Therapeutics makes that tension unusually visible: each successful prescription supports work whose eventual product might be an organ.